ImmunityBio Announces Collaboration with BeiGene on Confirmatory Ph 3 Trial of ANKTIVA and PD-1 Checkpoint Inhibitor Combination in NSCLC February 4, 2025
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals February 4, 2025
Patients Dosed in the First Cohort of the Ph 1/2 SOLARA Trial of BH-30643 for EGFR- and HER2-Mutated NSCLC January 28, 2025
First Patient Dosed in Ph 2 Study of JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable NSCLC January 28, 2025
Ph 2b Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma January 28, 2025
Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of SCLC January 28, 2025
FDA Clears 225Ac-Satoreotide Ph 1/2 Clinical Study in Patients with SCLC or Merkel Cell Carcinoma January 21, 2025
BLA submission of ANKTIVA planned in 2025 for 2/3L treatment of patients with NSCLC, who are progressing on checkpoint inhibitors January 21, 2025
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated NSCLC January 15, 2025
Asher Bio Announces Clinical Trial Collaboration & Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in SCLC Patients January 15, 2025
Development plans of NY-500, an AI-Optimized PD-1 x VEGF Bifunctional Antibody, announced in multiple oncology indications January 15, 2025
RYBREVANT® (amivantamab-vmjw) + LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in OS versus osimertinib January 15, 2025
FDA clears IND for Ph 1/2 clinical trial of REC-4539 in SCLC and MHRA clears IND for Ph 1 clinical trial of REC-3565 for B-cell malignancies January 15, 2025
European Commission approves RYBREVANT (amivantamab) + LAZCLUZE (lazertinib) for the 1L treatment of patients with EGFR-mutated advanced NSCLC January 7, 2025
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849 Targeting SCLC and NET Solid Tumors December 31, 2024
US FDA Accepts for Priority Review NDA for Taletrectinib for the Treatment of Advanced ROS1+ve NSCLC December 31, 2024
Datopotamab Deruxtecan Application in the EU for Patients with Advanced non-sqNSCLC Voluntarily Withdrawn December 31, 2024
FDA issues CRL for BLA for fixed combination of amivantamab and human hyaluronidase for SC amivantamab in patients with NSCLC with EGFR mutations December 26, 2024
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for 2L Treatment of ES-SCLC December 26, 2024
Initial clinical results from ongoing KYANITE-1 study of inhaled KB707 in patients with solid tumors of the lung announced December 25, 2024
